NutNow you can listen to Fox News items!
It was shown that weight loss surgery was five times more effective than the weekly injections of popular GLP-1 receptor, including semaglutids (such as Ozempic) and Tirzepatide (such as Mounjaro).
The finding comes from a recent study presented this week at the American Society for Metabolic and Bariric Surgery (ASMBS) 2025 Annual Scientific Meeting in Washington.
The researchers examined the “Real World” Electronic Medical Registers of 51,085 patients in Nyu Langone Health and NYC Health + Hospitals.
Hairdressers and medical experts confirm the temporary loss of hair that affects Ozempic users
All patients had a body mass index (BMI) of at least 35.
Either they had subjected to a bariatric surgery (sleeve gastrectomy or gastric by Roux en-y) or were prescribed in injected semaglutid or pulling between 2018 and 2024.
It was shown that weight loss surgery was five times more effective than the weekly injections of popular GLP-1 receptor agonists. (Istock)
(Sleeve gastrectomy reduces stomach size to help obese patients lose weight; gastric bypass involves cutting digestive tract to prevent a portion of the small intestine, according to the Mayo clinic.)
Patients who had one of the bariatry surgeries had lost an average of 58 pounds two years later, while those who had taken a GLP-1 prescription drug for at least six months lost 12 pounds, according to researchers.
Low -calorie diets linked to a surprising effect of mental health, according to new research
The surgical results accounted for 24% of total weight loss compared to 4.7% of injectable medicines, according to the study press release.
Those who took the Drug-1 for a full year showed more weight loss (7%), but even less than those who had suffered one of the surgeries.
Patients who had one of the bariatry surgeries had lost an average of 58 pounds two years later, while those who had taken a GLP-1 prescription drug for at least six months lost 12 pounds. (Istock)
These results differ from the results of clinical trials.
“Clinical trials show a weight loss between 15% and 21% for GLP-1, but this study suggests that weight loss in the real world is considerably lower even for patients who have active recipes for a whole,” said the author of the main study Avery Brown, MD, a surgical resident in Nyu Langone Health, in the press release.
Click here to get the Fox News app
According to Brown, 70% of GLP-1 patients can suspend treatment in a year, according to Brown.
“Patients with GLP-1 may need to adjust their expectations, adhere closer to treatment or opt for metabolic and bariatric surgery to achieve desired results,” he advised.
The surgical results accounted for 24% of total weight loss compared to 4.7% of injectable drugs.
In future studies, researchers are planning to explore strategies for improving the results for GPP-1 patients and identify which patients are better candidates for surgery versus injectable medicines, he said the launch.
The prevalence of GLP-1 drugs is higher than bariatric surgeries. Studies show that about 12% of Americans have taken a GP-1, while currently 6% take them.
Click here to register -you are in our health newsletter
However, more than half of the patients stop taking them after a year and 72% leave them after two years, according to the research.
Only about 1% of patients who comply with the criteria of metabolic and bariatric surgeries suffered one of these procedures by 2023, according to ASMBS.
Only about 1% of patients who meet the criteria of metabolic and bariatric surgeries were subjected to one of these procedures by 2023. (AP Photo/Kirsty Wigglesworth, file)
The study was financed by grants from the National Translational Science Advancement Center at National Health Institutes (NIH).
Novo Nordisk, a manufacturer of Ozempic and Wegovy, rejected a comment request.
For more health items, visit www.foxnews.com/health
Fox News Digital also contacted researchers and Eli Lilly, a manufacturer of Mounjaro and Zepbound.
#Weight #loss #surgery #praises #Ozempical #Popular #Treatment #comparison
Image Source : www.foxnews.com